048410 — Hyundai Bioscience Co Share Price
0.000.00%
Last trade - 00:00- KR₩530bn
- KR₩553bn
- KR₩15bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.47 | ||
| Price to Tang. Book | 84.72 | ||
| Price to Free Cashflow | 6,071.09 | ||
| Price to Sales | 35.29 | ||
| EV to EBITDA | 388.85 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.97% | ||
| Return on Equity | -16.36% | ||
| Operating Margin | 5.26% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 12,511.42 | 9,241.49 | 7,851.58 | 9,481.38 | 15,050.03 | n/a | n/a | -12.94% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
HYUNDAI BIOSCIENCE CO., LTD. it is a Korea-based company mainly engaged in the manufacturing and sale of bio cosmetics and hair tonic products. It develops functional daily necessities such as shampoos, mask packs, creams, and tumor-targeted drug. The Company also sells liquid crystal display (LCD) monitors and digital signage display products. The Company distributes its products in domestic market, as well as to the overseas markets, including Europe, America and Japan.
Directors
- Sang Gi Oh CEO (53)
- Je Man Jang COO (56)
- Yeong Gwon Jung OTH (46)
- Chang Hyeon Lee OTH (50)
- Jong Sik Park OTH (60)
- Jin Ho Choi NID (65)
- Sang Hyeok Han NID (52)
- Hong Jae Lee NID (52)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 25th, 2000
- Public Since
- August 8th, 2002
- No. of Shareholders
- 62,209
- No. of Employees
- 74
- Sector
- Personal & Household Products & Services
- Industry
- Consumer Defensives
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 48,019,214
- Address
- 106, Apogongdan-Gil, Apo-Eup, GIMCHEON, 39670
- Web
- http://www.hyundaibioscience.com/
- Phone
- +82 215443194
- Auditors
- KPMG Samjong Accounting Corp
Upcoming Events for 048410
Q2 2025 Hyundai Bioscience Co Ltd Earnings Release
Similar to 048410
Ark Solutions
Korea Exchange - KOSDAQ
Barunson Co
Korea Exchange - KOSDAQ
Bbia Co
Korea Exchange - KOSDAQ
BeautySkin Co
Korea Exchange - KOSDAQ
Bonne Co
Korea Exchange - KOSDAQ
FAQ
What is the Hyundai Bioscience Co share price?
As of Today at 21:03 UTC, shares in Hyundai Bioscience Co are trading at KR₩11,060. This share price information is delayed by 15 minutes.
How has the Hyundai Bioscience Co share price performed this year?
Shares in Hyundai Bioscience Co last closed at KR₩11,060 and the price had moved by -41.35% over the past 365 days. In terms of relative price strength the Hyundai Bioscience Co share price has underperformed the FTSE Developed Asia Pacific Index by -40.68% over the past year.
What are the analyst and broker recommendations for Hyundai Bioscience Co?
There is no consensus recommendation for this security.
Find out moreWhat is the Hyundai Bioscience Co dividend yield?
Hyundai Bioscience Co does not currently pay a dividend.
Does Hyundai Bioscience Co pay a dividend?
Hyundai Bioscience Co does not currently pay a dividend.
When does Hyundai Bioscience Co next pay dividends?
Hyundai Bioscience Co does not currently pay a dividend.
How do I buy Hyundai Bioscience Co shares?
To buy shares in Hyundai Bioscience Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Hyundai Bioscience Co?
As of the previous close price of KR₩11,060, shares in Hyundai Bioscience Co had a market capitalisation of KR₩530bn.
Where are Hyundai Bioscience Co shares listed?
Here are the trading details for Hyundai Bioscience Co:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 048410
What kind of share is Hyundai Bioscience Co?
Based on an overall assessment of its quality, value and momentum Hyundai Bioscience Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Hyundai Bioscience Co share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Hyundai Bioscience Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hyundai Bioscience Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -27.64%.
As of the last closing price of KR₩11,060, shares in Hyundai Bioscience Co were trading -26.39% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Hyundai Bioscience Co PE Ratio?
The Hyundai Bioscience Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩11,060.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Hyundai Bioscience Co?
Hyundai Bioscience Co's management team is headed by:
- Sang Gi Oh - CEO
- Je Man Jang - COO
- Yeong Gwon Jung - OTH
- Chang Hyeon Lee - OTH
- Jong Sik Park - OTH
- Jin Ho Choi - NID
- Sang Hyeok Han - NID
- Hong Jae Lee - NID